Sema AKİNCİ, Ahmet YALCİN, Arife ULAS, Kamile SİLAY

How Safe is Dabigatran in Elderly?

Burada Dabigatran kullanımı sırasındaki gastrointestinal kanama olgusu sunularak yaşlı hastalarda ilaç-ilaç etkileşim riskini vurgulamak amaçlanmıştır. Nonvalvüler atriyel fibrilasyon nedeni ile dabigatran ve nifedipin tedavisi alan 87 yaşındaki bayan hasta, gastrointestinal kanama şikayeti ile başvurmuştur. Yapılan endoskopi ve kolonoskopi sonucunda bir patoloji tespit edilememiştir. Kanama spontan olarak durmuştur. Vakamız dabigatran ile tedavi edilen hastalarda ileri yaşın yanısıra ilaç etkileşimlerinin de kanama riskini artırabileceğini göstermektedir. Klinisyenler bu ilaçları geriatrik populasyonda, özellikle 85 yaş üzerinde dikkatli bir şekilde kullanmalıdır.

Yaşlı Hastalarda Dabigatran Kullanımı ne kadar Güvenli?

The aim is to report a case of dabigatran induced gastrointestinal bleeding without any obvious source and emphasize the risk of drug interaction in an elderly patient. An 87 year-old female who was treated with dabigatran and nifedipine for nonvalvular atrial fibrillation developed gastrointestinal bleeding. Endoscopy and colonoscopy was performed and no pathology was identified. Bleeding stopped spontaneously. Our case suggests that drug interactions may increase the risk of bleeding additional to old age in patients who are treated with dabigatran. Clinicians should use these medications with caution in geriatric population particularly over 85 years old.

PDF

___

Pradaxa (dabigatran etexilate mesylate) capsules [prescribing information]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; September 2014.
Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008; 47: 285-95.
Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation [published correction appears in N Engl J Med. 2010;363:1877]. N Engl J Med. 2009; 361: 1139-51.
Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etixilate: an open-label, parallel-group, single centre study. Clin Pharmacokinet. 2010; 49: 259-68.
Institute for Safe Medication Practices. Monitoring FDA MedWatch Reports: Anticoagulants www.ismp.org/QuarterWatch/pdfs/2011Q4.pdf. Published May 31, 2012.
Gosselin RC, Dwyre DM, Dager WE. Measuring dabigatran concentrations using a chromogenic ecarin clotting time assay. Ann Pharmacother. 2013;47: 1635-40.
Anastasia L. A., Katie S. Buehler, Sun H. Min, Margaret Riley, Michael W. Daly. Evaluation of Dabigatran for Appropriateness of Use and Bleeding Events in a Community Hospital Setting. Am Health Drug Benefits. 2014; 7: 376-84
Wittkowsky AK. Novel oral anticoagulants and their role in clinical practice. Pharmacotherapy. 2011; 31: 1175-1191.
Béné J1, Saïd W, Rannou M, Deheul S, Coupe P, Gautier S. Rectal bleeding and hemostatic disorders induced by dabigatran etexilate in 2 elderly patients. Ann Pharmacother. 2012;46: e14.